| [ Summary ] |
Triple therapy of telaprevir with peginterferon and ribavirin significantly improves rates of sustained virological response in patients with HCV genotype 1 infection, who had not received previous treatment, and patients who had a previous relapse. Amino acid substitution of HCV core region and IL28B genotype are also useful as predictors of viral response to triple therapy. However, the sustained virological response rates to triple therapy are lower in patients who had a previous non response, so the suitable patients for triple therapy should be selected based on the risk of hepatocellular carcinoma. Furthermore, amino acid substitution of core region, alpha-fetoprotein level, and type of previous response could predict viral response to triple therapy in patients who had a previous non response. |